DK3976581T3 - Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine - Google Patents
Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine Download PDFInfo
- Publication number
- DK3976581T3 DK3976581T3 DK20725728.8T DK20725728T DK3976581T3 DK 3976581 T3 DK3976581 T3 DK 3976581T3 DK 20725728 T DK20725728 T DK 20725728T DK 3976581 T3 DK3976581 T3 DK 3976581T3
- Authority
- DK
- Denmark
- Prior art keywords
- sulfonylphenoxy
- fluoro
- methane
- propyl
- amine
- Prior art date
Links
- OSBPYFBXSLJHCR-UHFFFAOYSA-N n-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]propan-1-amine Chemical class CCCNCCOC1=CC(F)=CC(S(C)(=O)=O)=C1 OSBPYFBXSLJHCR-UHFFFAOYSA-N 0.000 title 1
- 150000003892 tartrate salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19176514 | 2019-05-24 | ||
| EP20166361 | 2020-03-27 | ||
| PCT/EP2020/064046 WO2020239568A1 (en) | 2019-05-24 | 2020-05-20 | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3976581T3 true DK3976581T3 (da) | 2024-01-22 |
Family
ID=70682855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20725728.8T DK3976581T3 (da) | 2019-05-24 | 2020-05-20 | Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12275694B2 (enExample) |
| EP (2) | EP3976581B1 (enExample) |
| JP (1) | JP7623958B2 (enExample) |
| KR (1) | KR102892833B1 (enExample) |
| CN (1) | CN113853369B (enExample) |
| AU (1) | AU2020286003B2 (enExample) |
| BR (1) | BR112021023563A2 (enExample) |
| CA (1) | CA3140805A1 (enExample) |
| CL (1) | CL2021003115A1 (enExample) |
| CO (1) | CO2021016556A2 (enExample) |
| DK (1) | DK3976581T3 (enExample) |
| ES (2) | ES2970361T3 (enExample) |
| FI (1) | FI3976581T3 (enExample) |
| IL (1) | IL288271B2 (enExample) |
| JO (1) | JOP20210312A1 (enExample) |
| MX (1) | MX2021014271A (enExample) |
| PH (1) | PH12021552844A1 (enExample) |
| PL (1) | PL3976581T3 (enExample) |
| PT (1) | PT3976581T (enExample) |
| SG (1) | SG11202112165QA (enExample) |
| WO (1) | WO2020239568A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12275694B2 (en) | 2019-05-24 | 2025-04-15 | Irl 790 Ab | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
| JP7688690B2 (ja) | 2020-07-28 | 2025-06-04 | スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | ピリミジン系化合物の塩、結晶形およびその調製方法 |
| JP2023548429A (ja) * | 2020-11-10 | 2023-11-16 | インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー | パーキンソン病、特にｌ－ｄｏｐａ誘発性ジスキネジアのための医薬品に対する感作の予防または軽減における使用のための［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミン（メスドペタム） |
| WO2024042540A1 (en) * | 2022-08-24 | 2024-02-29 | Alkem Laboratories Limited | Mesdopetam compositions |
| CA3268423A1 (en) | 2022-09-21 | 2024-03-28 | Assia Chemical Industries Ltd. | Solid state forms of mesdopetam and salts thereof |
| GB202312055D0 (en) | 2023-08-07 | 2023-09-20 | Ipsen Biopharm Ltd | Pharmaceutical compositions |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51123821A (en) | 1975-04-18 | 1976-10-28 | Nippon Kayaku Co Ltd | An algicide and protective agent |
| US4128574A (en) * | 1976-10-04 | 1978-12-05 | General Electric Company | Method for making organic polycarboxylic acids |
| GB8823405D0 (en) | 1988-10-05 | 1988-11-09 | Erba Carlo Spa | Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines |
| ES2169102T3 (es) | 1994-10-14 | 2002-07-01 | Merck Patent Gmbh | (r)-(-)-2-(5-(4-fluorfenil)-3-piridilmetilaminometil)-cromano como agente activo sobre el sistema nervioso central. |
| SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| DOP2001000189A (es) | 2000-06-30 | 2002-03-30 | Pfizer Prod Inc | Benzofenonas y sulfonas como inhibidores de la captación de glicina |
| JP2006193494A (ja) | 2005-01-17 | 2006-07-27 | Dainippon Ink & Chem Inc | ４級アンモニウム系化合物を有効成分とする心臓疾患治療剤 |
| CN101203511A (zh) | 2005-06-23 | 2008-06-18 | 阿斯利康(瑞典)有限公司 | 作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物 |
| WO2007063789A1 (ja) | 2005-11-29 | 2007-06-07 | Kissei Pharmaceutical Co., Ltd. | 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| WO2007072041A1 (en) | 2005-12-23 | 2007-06-28 | Astex Therapeutics Limited | Therapeutic compounds |
| AU2007218086A1 (en) * | 2006-02-15 | 2007-08-30 | M's Science Corporation | Piperazine derivatives |
| CA2687721A1 (en) * | 2007-06-08 | 2008-12-18 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| TW200932225A (en) * | 2007-12-14 | 2009-08-01 | Lundbeck & Co As H | 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine |
| JP2011519839A (ja) | 2008-04-29 | 2011-07-14 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | ドーパミン神経伝達のモジュレーター |
| WO2009133110A1 (en) | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
| MX2010011724A (es) | 2008-04-29 | 2010-11-30 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
| US9006227B2 (en) * | 2011-04-19 | 2015-04-14 | Integrative Research Laboratories Sweden Ab | Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| MX391727B (es) | 2016-02-08 | 2025-03-21 | Merck Patent Gmbh | Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina. |
| EP3625213B1 (en) | 2017-05-19 | 2023-03-08 | Integrative Research Laboratories Sweden AB | (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine fumarate, a process for its preparation and uses thereof |
| SG11202000833YA (en) * | 2017-08-07 | 2020-02-27 | Suven Life Sciences Ltd | Fluoropiperidine compounds as pure 5-ht6 receptor antagonists |
| WO2020110128A1 (en) | 2018-11-29 | 2020-06-04 | Prilenia Neurotherapeutics Ltd. | Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia |
| US12275694B2 (en) | 2019-05-24 | 2025-04-15 | Irl 790 Ab | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
-
2020
- 2020-05-20 US US17/612,902 patent/US12275694B2/en active Active
- 2020-05-20 PH PH1/2021/552844A patent/PH12021552844A1/en unknown
- 2020-05-20 KR KR1020217037818A patent/KR102892833B1/ko active Active
- 2020-05-20 FI FIEP20725728.8T patent/FI3976581T3/fi active
- 2020-05-20 DK DK20725728.8T patent/DK3976581T3/da active
- 2020-05-20 SG SG11202112165QA patent/SG11202112165QA/en unknown
- 2020-05-20 EP EP20725728.8A patent/EP3976581B1/en active Active
- 2020-05-20 CN CN202080036829.0A patent/CN113853369B/zh active Active
- 2020-05-20 EP EP23190702.3A patent/EP4292653B1/en active Active
- 2020-05-20 BR BR112021023563A patent/BR112021023563A2/pt unknown
- 2020-05-20 JP JP2021569359A patent/JP7623958B2/ja active Active
- 2020-05-20 PT PT207257288T patent/PT3976581T/pt unknown
- 2020-05-20 IL IL288271A patent/IL288271B2/en unknown
- 2020-05-20 PL PL20725728.8T patent/PL3976581T3/pl unknown
- 2020-05-20 AU AU2020286003A patent/AU2020286003B2/en active Active
- 2020-05-20 CA CA3140805A patent/CA3140805A1/en active Pending
- 2020-05-20 ES ES20725728T patent/ES2970361T3/es active Active
- 2020-05-20 WO PCT/EP2020/064046 patent/WO2020239568A1/en not_active Ceased
- 2020-05-20 MX MX2021014271A patent/MX2021014271A/es unknown
- 2020-05-20 ES ES23190702T patent/ES3072819T3/es active Active
-
2021
- 2021-11-24 JO JOP/2021/0312A patent/JOP20210312A1/ar unknown
- 2021-11-24 CL CL2021003115A patent/CL2021003115A1/es unknown
- 2021-12-06 CO CONC2021/0016556A patent/CO2021016556A2/es unknown
-
2025
- 2025-03-14 US US19/080,430 patent/US20250243155A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3976581T3 (pl) | Sole kwasu winowego [2-(3-fluoro-5-metanosulfonylofenoksy)etylo](propylo)aminy | |
| EP4083038A4 (en) | PYRIDAZINYL THIAZOLECARBOXAMIDE COMPOUND | |
| DK4061812T3 (da) | Forbindelser som er nyttige som inhibitorer af heliosprotein | |
| CY2024024I2 (el) | Υδροχλωρικα αλατα ν-(κυανομεθυλ)-4-(2-(4- μορφολινοφαινυλαμινο)πυριμιδιν-4-υλ)βενζαμιδιου | |
| HUE069570T2 (hu) | Nitril-tartalmú vegyületek gyógyszerként történõ alkalmazásra | |
| DK3743411T3 (da) | Herbicidt virksomt 3-phenylisoxazolin-5-carboxamider af cyclopentenylcarbonsyrederivater | |
| IL288997A (en) | Salt forms of bempedoic acid and methods for using the same | |
| IL289439A (en) | Heterocyclic compounds as bet inhibitors | |
| CY1121071T1 (el) | Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων | |
| EP3402799A4 (en) | Heterocyclic compounds as RSV inhibitors | |
| DK4055021T3 (da) | Heterocykliske rip1-inhiberende forbindelser | |
| IL286218A (en) | Solid state forms of ripretinib | |
| LT3993807T (lt) | Vaistą apimančios vandeninės kompozicijos ph stabilizavimo būdas | |
| DK3658552T3 (da) | Fremgangsmåde til fremstilling af n-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamid ved reaktion af den tilsvarende amin med et 3-halogen-propionylchlorid | |
| IL285721A (en) | Methods of making high enantioselective secondary alcohols | |
| EP3414256A4 (en) | AMINO SALT OF OBETICHOLIC ACID | |
| EA201401084A1 (ru) | Соли 5-[(1r)-2({2-[4-(2,2-дифтор-2-фенилэтокси)фенил]этил}амино)-1-гидроксиэтил]-8-гидроксихинолин-2(1н)-она | |
| IL238011A0 (en) | Derivatives of n-(2-(cyclic amine)ethyl)benzamide as p2x7 inhibitors | |
| EP4003323A4 (en) | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | |
| HUE063674T2 (hu) | Eljárás N-(amino-imino-metil)-2-aminoetánsav (III) metastabil kristálymódosulatának elõállítására | |
| EP3919485A4 (en) | CRYSTALS OF QUINOLINE DERIVATIVES | |
| DK2819998T3 (da) | Krystallinske former af 1-(3-tert-butyl-1-P-tolyl-1H-pyrazol-5-yl)-3-(5-fluor-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)ureahydrochlorid | |
| PL4082616T3 (pl) | Pochodna amidowa kwasu alifatycznego | |
| IL290181A (en) | Process for the preparation of fluensulfone | |
| HUE066959T2 (hu) | Eljárás anilin tisztítására |